2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 275-277
Transcriptional and epigenetic remodelling orchestrate immune evasion and create therapeutic vulnerabilities in lymphoid malignancies, by providing lineage platicity and competitive fitness, inducing extracellular vesicles secretion to modulate the immune microenvironment, downregulating endogenous retroelements, and reorganizing enhancer condensates.
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Pediatric, Animal Model
PAPER

46 Epigenetic reactivation of endogenous retroelements stimulates anti-tumor immunity and therapeutic vulnerabilities in diffuse large B-cell lymphoma

Mohamad Ali Najia, PhD, Deepak Jha, PhD2, Alaa Kassim Ali, PhD3, Rizwan Romee, MD4, George Daley, MD, PhD5
1 Boston Children's Hospital, Boston, Massachusetts, United States, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Diffuse large B-cell lymphoma (DLBCL) frequently evades immunosurveillance through restricted antigen presentation and low immunogenicity, limiting the durability of responses to cellular immunotherapies. Endogenous retroelements (EREs) include vestigial remnants of retroviral infections in the human genome and can trigger tumor immunogenicity when aberrantly active. We previously demonstrated that specific EREs contribute to normal B-cell regulatory networks, yet their roles in B-cell malignancies remain poorly defined. We hypothesized that epigenetically modulating ERE activity can undermine malignant regulatory networks and stimulate durable antitumor immunity in DLBCL.

We first analyzed scRNA-seq datasets from primary DLBCL patient lymph node biopsies to define ERE-associated malignant transcriptional programs and compared them with Hodgkin lymphoma patients, which are generally responsive to immune checkpoint blockade. Expression of EREs, specifically long-terminal repeat elements (LTRs), and interferon signaling programs were attenuated genome-wide in 14/15 DLBCL cases relative to patient-matched non-malignant B-cells. Conversely, LTRs were aberrantly active in Hodgkin lymphoma patients, correlating with inflammatory signaling associated with durable immunotherapy responses.

To systematically modulate EREs and their transcriptional programs, we performed CRISPR-interference Perturb-seq screens across a compendium of DLBCL cell lines. Critically, we leveraged computational approaches to quantify ERE expression from scRNA-seq data to understand how gene perturbations affect the coding and ERE transcriptomes in single cells. Knockdown of SETDB1, KDM1A, CHD4 and HUSH complex members consistently derepressed EREs across germinal center (GCB) and activated B-cell (ABC) subtypes of DLBCL. In particular, SETDB1 knockdown most significantly derepressed EREs genome-wide and induced interferon programs associated with durable immunotherapy responses. Validation of Perturb-seq hits with the generation of CRISPR knockout cells revealed that SETDB1 loss resulted in dsRNA accumulation and IRF7-mediated viral mimicry via MDA-5 signaling. Co-culture of SETDB1 knockout OCI-Ly1 cells with peripheral blood natural killer (NK) cells resulted in enhanced NK activation and NK-mediated cytotoxicity compared to control sgAAVS1 OCI-Ly1 cells.

We next leveraged our Perturb-seq data to understand how gene perturbations influence transcriptional programs in DLBCL cells. We defined transcriptional programs using non-negative matrix factorization, which revealed that various LTRs contributed to a GCB identity program. Knockdown of SETDB1 significantly increased the activity of this program in single cells, including specific therapeutic targets within the program. First, MS4A1 was one of the top genes contributing to the GCB identity program and we further corroborated increased cell-surface expression in SETDB1 knockout cells via flow cytometry for CD20. We exploited this phenotype to demonstrate that SETDB1 knockout DLBCL cells were significantly more susceptible to anti-CD20 therapeutics in vitro and in vivo via treatment with rituximab and peripheral blood NK cells, mosunetuzumab and peripheral blood T cells, and CD20-directed CAR-T cells in a murine xenograft model. Finally, analysis of Perturb-seq transcriptional programs also revealed transcriptional upregulation of EZH2 in SETDB1 knockdown cells, which rendered the traditionally insensitive ABC DLBCL subtype sensitive to the EZH2 inhibitor, tazemetostat. Furthermore, base-editor tiling mutagenesis screens of SETDB1 nominated that disruption of the SET domain is critical to elicit sensitivity to EZH2 inhibition.

Our work reveals that EREs contribute to dysregulated DLBCL transcriptional programs and that ERE reactivation via modulation of SETDB1 can instigate viral mimicry and antitumor immunity. Furthermore, this study demonstrates that the inclusion of EREs in high-content genetic screens can complement insights from gene expression to enrich our understanding of disease pathology. Collectively, our findings provide a mechanistic rationale for novel therapeutic targets and combination therapies in B-cell malignancies.

Mohamad Ali Najia, PhD: No relevant conflicts of interest to declare.